Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIF 1149 BS - single rising doses
Drug: Placebo

First Posted Date: 2014-07-25

Last Posted Date: 2014-07-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02199899

Micardis®. Observational Study in Patients With Essential Hypertension

Completed

Conditions: Hypertension

Interventions: Drug: Low dose of Telmisartan, once daily
Drug: High dose of Telmisartan, once daily

First Posted Date: 2014-07-25

Last Posted Date: 2014-07-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4532

Registration Number: NCT02200094

A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: High dose of COZAAR® / LORZAAR®, once daily
Drug: High dose of MICARDIS®, once daily
Drug: Low dose of COZAAR® / LORZAAR®, once daily
Drug: Low dose of MICARDIS®, once daily
Drug: Placebo

First Posted Date: 2014-07-25

Last Posted Date: 2014-07-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 387

Registration Number: NCT02200653

Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache

Phase 2

Completed

Conditions: Migraine Disorders

Interventions: Drug: Placebo
Drug: BIBN 4096 BS

First Posted Date: 2014-07-23

Last Posted Date: 2014-07-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 126

Registration Number: NCT02198339

Study to Determine Tolerability After Intravenous Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBN 4096 BS - in single rising doses
Drug: Placebo

First Posted Date: 2014-07-23

Last Posted Date: 2014-07-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 55

Registration Number: NCT02198352

Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BIIX 1 XX inhalation solution

First Posted Date: 2014-07-23

Last Posted Date: 2014-07-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 54

Registration Number: NCT02198287

Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BIBN 4096 BS- in single rising doses

First Posted Date: 2014-07-23

Last Posted Date: 2014-07-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02198326

A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX in Healthy Male Volunteers

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BIIX 1 XX - D1
Drug: BIIX 1 XX - D2
Drug: Placebo
Drug: BIIX 1 XX - D3

First Posted Date: 2014-07-23

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT02198313

Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: BIBH 1

First Posted Date: 2014-07-23

Last Posted Date: 2014-07-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25

Registration Number: NCT02198274

Effectiveness and Safety of Synvisc® Versus Usual Treatments in Patients With Knee Osteoarthritis

Phase 4

Completed

Conditions: Osteoarthritis

Interventions: Drug: Hylan G-F 20
Drug: Standard treatment
Procedure: Physiotherapy
Procedure: Hydrotherapy

First Posted Date: 2014-07-22

Last Posted Date: 2014-07-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 518

Registration Number: NCT02197026

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy